Skip to search formSkip to main contentSkip to account menu

Amsalog

National Institutes of Health

Related topics

Related topics

2 relations
CI 921

Broader (1)

asulacrine

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2001
2001
A phase I trial of amsalog (CI-921) administered by intravenous infusion using a 5-day schedule
Purpose: Amsalog, a derivative of 9-aminoacridine, is an inhibitor of topoisomerase II. Early studies of intravenous amsalog… 
2001
2001
A study of amsalog (CI-921) administered orally on a 5-day schedule, with bioavailability and pharmacokinetically guided dose escalation
Abstract.Purpose: Amsalog is a derivative of 9-aminoacridine. Phase I studies using intravenous (i.v.) amsalog have shown the… 
1996
1996
Enhanced therapeutic effect of amsalog (CI-921) in combination with cisplatin in vitro and in vivo.
CI-921, the 5-methyl-4-carboxamide analog of amsacrine, in combination with cisplatin produced a 6-fold better cell kill in vitro… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)